Tuberculosis Treatment Clinical Trials

Tuberculosis (TB) remains a leading cause of infectious mortality worldwide, driving an active research agenda to optimise and shorten treatment. Clinical trials span early‐phase studies of novel compounds through large, multicentre Phase III non‐inferiority trials comparing candidate regimens with the six-month standard of care. Key priorities include shortening duration, improving safety profiles, overcoming drug resistance and stratifying patients by risk of unfavourable outcomes. Recent advances have focused on fluoroquinolone- and rifapentine-based regimens, innovative trial designs that integrate extended follow-up and risk-based treatment allocation, and the use of surrogate markers such as sputum culture conversion to accelerate decision-making. Global efforts increasingly combine pharmacokinetic, radiographic and microbiological data to tailor regimens for both rifampin-susceptible and rifampin-resistant TB. The ultimate goal is to deliver shorter, safer and more effective therapies that are affordable and accessible in high-burden settings, thereby reducing incidence, preventing relapse and curbing transmission.

Research from Nature Portfolio

Recent studies have refined risk stratification for a four-month rifapentine-moxifloxacin regimen in drug-susceptible pulmonary TB. Analyses of demographic, clinical and pharmacokinetic data identified low rifapentine exposure and markers of extensive disease on chest radiography as predictors of unfavourable outcomes. A simple risk score was developed to classify patients into easier-, moderately-harder and harder-to-treat phenotypes, suggesting that low-risk individuals may safely receive shorter courses while high-risk patients might require dose adjustments or extended therapy.

A foundational patient-level pooled analysis of multiple treatment-shortening trials evaluated factors such as baseline smear grade, cavitation and adherence, demonstrating that four-month regimens were non-inferior in participants with minimal disease. This work provided the first robust phenotypic definitions of hard-to-treat TB and supported a stratified-medicine approach, moving beyond one-size-fits-all treatment to targeted duration selection.

Tuberculosis Treatment Clinical Trials publication trend

The graph below shows the total number of articles in tuberculosis treatment clinical trials across all publications each year (not limited to Nature Index journals).

Technical terms

Non-inferiority trial: A study designed to demonstrate that a new treatment’s efficacy is not unacceptably worse than that of a standard regimen by a pre-specified margin.

Risk stratification: Classification of patients into groups based on clinical, microbiological or pharmacological factors that predict treatment response or adverse events.

Target regimen profile: A formal outline of minimal and optimal attributes—such as duration, safety and efficacy—that future drug combinations should meet.

Culture conversion: The point during therapy when a patient’s sputum samples consistently show no growth of Mycobacterium tuberculosis, indicating bacteriological response.

Phase III trial: A large, definitive study that compares new treatments with established standards to confirm efficacy and monitor safety before regulatory approval.

References

1. Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis. The Lancet Global Health (2024).
2. Risk-stratified treatment for drug-susceptible pulmonary tuberculosis. Nature Communications (2024).
3. Target regimen profiles for tuberculosis treatment. Bulletin of the World Health Organization (2024).
4. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nature Medicine (2018).
5. A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP). BMC Medicine (2016).